O. Nicolas

发表

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.

Denis Labrecque, Darius Bilimoria, R. Bethell, 2004 .

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across different compound classes

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

IMI – Oral biopharmaceutics tools project – Evaluation of bottom‐up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results

Amitava Mitra, Jian Lin, Mai Anh Nguyen, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

In Vitro Phenotypic Characterization of Hepatitis C Virus NS3 Protease Variants Observed in Clinical Studies of Telaprevir

Tara L. Kieffer, B. G. Rao, O. Nicolas, 2013, Antimicrobial Agents and Chemotherapy.

Observed in Clinical Studies of Telaprevir Hepatitis C Virus NS3 Protease Variants Phenotypic Characterization of In Vitro

Tara L. Kieffer, B. G. Rao, O. Nicolas, 2013 .

PBPK modeling of irbesartan: incorporation of hepatic uptake

O. Nicolas, S. Klieber, S. Gerbal-Chaloin, 2015, Biopharmaceutics & drug disposition.

IMI - Oral biopharmaceutics tools project - Evaluation of bottom-up PBPK prediction success part 4: Prediction accuracy and software comparisons with improved data and modelling strategies.

M. Jamei, L. Aarons, M. Bolger, 2020, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

Differential Effects of Omeprazole and Pantoprazole on the Pharmacodynamics and Pharmacokinetics of Clopidogrel in Healthy Subjects: Randomized, Placebo‐Controlled, Crossover Comparison Studies

L. Bergougnan, O. Nicolas, D. Angiolillo, 2011, Clinical pharmacology and therapeutics.

Pharmacological Properties of a New Antimalarial Bisthiazolium Salt, T3, and a Corresponding Prodrug, TE3

H. Vial, F. Bressolle, O. Nicolas, 2005, Antimicrobial Agents and Chemotherapy.

Quantification of the expression and inducibility of 12 rat cytochrome P450 isoforms by quantitative RT–PCR

O. Nicolas, N. Rioux, B. Hamelin, 2006, Journal of biochemical and molecular toxicology.

Genotypic and Phenotypic Analyses of Hepatitis C Virus Variants Observed in Clinical Studies of VX-222, a Nonnucleoside NS5B Polymerase Inhibitor

Tara L. Kieffer, B. G. Rao, O. Nicolas, 2014, Antimicrobial Agents and Chemotherapy.

961 GENOTYPIC AND PHENOTYPIC ANALYSIS OF HCV NS5B VARIANTS SELECTED FROM PATIENTS TREATED WITH VCH-916

O. Nicolas, J. Bédard, I. Boivin, 2009 .

844 GENOTYPIC ANALYSIS OF HCV NS5B VARIANTS SELECTED FROM PATIENTS TREATED WITH VCH-759

O. Nicolas, J. Bédard, I. Boivin, 2008 .

CCNE1 amplification is synthetic lethal with PKMYT1 kinase inhibition

D. Durocher, R. Stocco, A. Roulston, 2021, Nature.

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 2: tertiary amides.

Darius Bilimoria, Lucille L'Heureux, R. Bethell, 2004, Bioorganic & medicinal chemistry letters.

Evaluation of VCH-759 monotherapy in hepatitis C infection.

O. Nicolas, J. Bédard, P. Ghali, 2009, Journal of hepatology.

935 IDENTIFICATION AND CHARACTERIZATION OF VCH-222, A NOVEL POTENT AND SELECTIVE NON-NUCLEOSIDE HCV POLYMERASE INHIBITOR

L. Chan, L. L'Heureux, D. Bilimoria, 2009 .

Discovery of Novel Allosteric HCV NS5B Inhibitors. 2. Lactam-Containing Thiophene Carboxylates.

B. G. Rao, S. Das, D. Bilimoria, 2017, ACS medicinal chemistry letters.

Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.

B. G. Rao, G. Iyer, L. Chan, 2016, Journal of medicinal chemistry.

Discovery of thiophene-2-carboxylic acids as potent inhibitors of HCV NS5B polymerase and HCV subgenomic RNA replication. Part 1: Sulfonamides.

Denis Labrecque, Darius Bilimoria, Lucille L'Heureux, 2004, Bioorganic & medicinal chemistry letters.

Synthesis and evaluation of NS5A inhibitors containing diverse heteroaromatic cores.

L. Chan, S. Das, Oswy Z. Pereira, 2015, Bioorganic & medicinal chemistry letters.

Crystal Structures of the RNA-dependent RNA Polymerase Genotype 2a of Hepatitis C Virus Reveal Two Conformations and Suggest Mechanisms of Inhibition by Non-nucleoside Inhibitors*

Meitian Wang, Darius Bilimoria, M. James, 2005, Journal of Biological Chemistry.

Identification of RP-6685, an Orally Bioavailable Compound that Inhibits the DNA Polymerase Activity of Polθ.

J. Falgueyret, R. Stocco, Hugo Poirier, 2022, Journal of medicinal chemistry.

HCV NS5B polymerase-bound conformation of a soluble sulfonamide inhibitor by 2D transferred NOESY.

F. Ni, R. Bethell, L. Chan, 2004, Bioorganic & medicinal chemistry letters.

Quantification of antimalarial bisthiazolium compounds and their neutral bioprecursors in plasma by liquid chromatography-electrospray mass spectrometry.

H. Vial, F. Bressolle, O. Nicolas, 2005, Clinical Chemistry.

Prodrugs of bisthiazolium salts are orally potent antimalarials.

H. Vial, F. Bressolle, O. Nicolas, 2004, Proceedings of the National Academy of Sciences of the United States of America.

CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect

O. Nicolas, X. Boulenc, C. Ollier, 2016, European Journal of Drug Metabolism and Pharmacokinetics.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 2: non-symmetric inhibitors with potent activity against genotype 1a and 1b.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-symmetric inhibitors with diyne and biphenyl linkers.

L. Chan, S. Das, L. L'Heureux, 2015, Bioorganic & medicinal chemistry letters.

CYP3A4-based drug–drug interaction: CYP3A4 substrates’ pharmacokinetic properties and ketoconazole dose regimen effect

O. Nicolas, X. Boulenc, C. Ollier, 2014, European Journal of Drug Metabolism and Pharmacokinetics.

Discovery of Novel Thiophene-Based, Thumb Pocket 2 Allosteric Inhibitors of the Hepatitis C NS5B Polymerase with Improved Potency and Physicochemical Profiles.

G. Iyer, L. Chan, C. Yannopoulos, 2016, Journal of medicinal chemistry.

Benzimidazole-containing HCV NS5A inhibitors: effect of 4-substituted pyrrolidines in balancing genotype 1a and 1b potency.

L. Chan, S. Das, Oswy Z. Pereira, 2015, Bioorganic & medicinal chemistry letters.